Present-day uses of niacin: Effects on lipid and non-lipid parameters

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1711-1717

  Sanyal, Sanjukta ^a   Karas, Richard H ^a   Kuvin, Jeffrey T ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

HDL cholesterol; Lipids; Niacin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; DEXTROTHYROXINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; LIPID; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ACANTHOSIS NIGRICANS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GOUT; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; INSOMNIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; METABOLIC SYNDROME X; MIGRAINE; MONOTHERAPY; MYOPATHY; PATIENT COMPLIANCE; PEPTIC ULCER; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS; LIPIDS; METABOLIC SYNDROME X; NIACIN;

EID: 34548098716     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1711     Document Type: Article

References (53)

1. ALTSCHUL R, HOFFER A, STEPHEN JD: Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. (1955) 54:558-559.
2. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults, executive summary of the third report of the national cholesterol education program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
3. TOTH PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol. (2005) 96(Suppl.):k50-k58.
4. ASSMANN G, SCHULTE H, VON ECKARDSTEIN A, HUANG Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atheresclerosis (1996) 124(Suppl. 1):S11-S20.
5. KUVIN JT, PATEL AR, SIDHU M et al.: Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am. J. Cardiol. (2003) 92(3):275-279.
6. BARTER PJ, RYE K: Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. (1996) 7:82-87.
7. FREDENRICH A, BAYER P: Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab. (2003) 29:201-205.
8. TALL AR: Plasma high density lipoproteins; metabolism and relationship to atherogenesis. J. Clin. Invest. (1990) 86:379-384.
9. KUJIRAOKA T, NANJEE MN, OKA T et al.: Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1653-1659.
10. NISSEN SE, TSUNODA T, TUZCU EM et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 290:2292-2300.
11. NEGRE-SALVAYRE A, DOUSSET N, FERRETTI G, BACCHETTI T, CURATOLA G, SALVAYRE R: Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic. Biol. Med. (2006) 41(7):1031-1040.
12. SOUDIJU W, WIJNGAARDEN IV, IJZERMAN AP: Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev. (2007).
13. GRUNDY SM, MOK HY, ZECH L, BERMAN M: Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. (1981) 22:24-36.
14. MORGAN JM, CAREY CM, LINCOFF A, CAPUZZI DM: The effects of niacin on lipoprotein subclass distribution. Prev. Cardiol. (2004) 7(4):182-187.
15. SAKAI T, KAMANNA VS, KASHYAP ML: Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1783-1789.
16. ATAC IA, PEKSEL A, YANARDAG R, SOKMEN BB, DOGER MM, BILEN ZG: The effect of combined treatment with niacin and chromium (III) chloride on different tissues of hyperlipemic rats. Drug Chem. Toxicol. (2006) 29(4):363-377.
17. KUVIN JT, DAVE DM, SLINEY KA et al.: Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. (2006) 98(6):743-745.
18. TAVINTHARAN S, SIVAKUMAR M, LIM SC, SUM CF: Niacin affects cell adhesion molecules and phsminogen activator inhihitor-1 in HepG2cells. Clinica Chimica Acta (2007) 376:41-44.
19. WESTPHAL S, BORUCKI K, TANEVA E, MAKAROVA R, LULEY C: Extended-release niacin raises adiponectin and leptin. Atherosclerosis (2006).
20. PIEPER JA: Overview of niacin formulations: difference in pharmacokinetics, efficacy and safety. Am. J. Health-Syst. Pharm. (2003) 60(Suppl. 2):S9-S14.
21. MORROW JD, AWAD JA, OATES JA, ROBERTS LJ II: IdentiFication of skin as a major site of prostaglandin D2 release following omi administration of niacin in humans. J. Invest. Dermatol. (1992) 98:812-815.
22. KAIJSER L, EKLUND B, OLSSON AG et al.: Dissociation of the effects of nicotinic acid on vasodilation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med. Biol. (1979) 57:114-117.
23. WILKIN JK, WILKING O, KAPP R, DONACHIE R, CHERNOSKY ME, BUCKNER J: Aspirin blocks nicotinic acid induced flushing. Clin. Pharmacol. Ther. (1982) 31:478-482.
24. PEIPHO RW: The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol. (2000) 86(Suppl.):L35-L40.
25. CEFALI EA, SIMMONS PD, STANEK EJ, MCGOVERN ME, KISSLING CJ: Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int. J. Clin. Pharmacol. Ther. (2007) 45:78-88.
26. VOGT A, KASSNER U, HOSTALEK U, STEINHAGEN-THIESSEN E: Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr. Med. Res. Opin. (2006) 22(2):417-425.
27. KNOPP RH, ALAGONA R DAVIDSON M et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism (1992) 41:879-881.
28. KNOPP RH: Evaluating niacin in its various forms. Am. J. Cardiol. (2000) 86(12A):L51-L56.
29. MCKENNEY J: New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. (2004) 164:697-705.
30. ALSHEIKH-ALI AA, KARAS RH: Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System). Am. J. Cardiol. (2007) 99:379-381.
31. ELAM MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral artery disease: the ADMIT study: a randomized trial. JAMA (2000) 284(10):1263-1270.
32. GRUNDY SM, VEGA GL, MCGOVERN ME et al.: Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. (2002) 162:1568-1576.
33. UK PROSPECTIVE DIABETES STUDY GROUP, PROSPECTIVE DIABETES STUDY 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care (1997) 20:1683-1687.
34. GARG A, GRUNDY SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA (1990) 264(6):723-726.
35. Clofibrate and niacin in coronary heart disease. JAMA (1975) 231(4):360-381.
36. CANNER PL, BERGE KG, WENGER NK et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. (1986) 8(6):1245-1255.
37. BLANKENHORN DH, NESSIM SA, JOHNSON RL, SANMARCO ME, AZEN SP, CASHIN-HEMPHILL L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.. JAMA (1987) 257(23):3233-3240.
38. BROWN G, ALBERS JJ, FISHER LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. (1990) 323:1289-1298.
39. BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary artery disease. N. Engl. J. Med. (2001) 345(22):1583-1592.
40. BAYS HE, DUJOVNE CA, MCGOVERN ME et al.: Comparison of once-daily, niaicin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. (2003) 91:667-672.
41. MCKENNEY JM, JONES PH, BAYS HE et al.: Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (COMPELL study). Atherosclerosis (2007).
42. KUVIN JT, RAMET ME, PATEL AR, PANDIAN NG, MENDELSOHN ME, KARAS RH: A novel mechanism for beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxtion and increased endothelial nitric oxide symhase expression. Am. Heart J. (2002) 144(1):165-172.
43. TAYLOR AJ, SULLENBERGER LE, LEE HJ, LEE JK, GRACE KA: Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2, a double-blind placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110:3512-3517.
44. TAYLOR AJ, LEE HJ, SULLENBERGER LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. (2006) 22(11):2243-2250.
45. ZHAO XQ, MORSE JS, DOWDY AA et al.: Safety and tolerabillty of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL atheroscleorosis treatment study). Am. J. Cardiol. (2004) 93:307-312.
46. RUBENFIRE M: Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspecialty on patient compliance to treatment (IMPACT) study. Am. J. Cardiol. (2004) 94:306-311
47. ITO MK: The metabolic syndrome:. pathophysiology, clinical relevance, and use of niacin. Ann. Pharmacother. (2004) 38(2):277-285.
48. ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24:683-689.
49. KAWAMOTO R, TOMITA H, INOUE A, OHTSUKA N, KAMITANI A: Metabolic syndrome may be a risk factor for early carotid atherosclerosis in women but not in men. J. Atheroscler. Thromb. (2007) 14(1):36-43.
50. BODEN WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease, assessing the data form framingham to the veterans affairs high-density lipoprotein intervention trial. Am. J. Cardiol.(2000) 86(Suppl.):L19-L22.
51. CANNER PL, FURBERG CD, MCGOVERN ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am. J. Cardiol. (2006) 97:477-479.
52. MOSCA L, APPEL LJ, BENJAMIN EJ et al.: Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 109:672-693.
53. MOSCA L: Management of dyslipidemia in women in the post-hormone therapy era. J. Gen. Intern. Med. (2005) 20:297-305.